IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis

Rasmus Siersbæk; Valentina Scabia; Sankari Nagarajan; Igor Chernukhin; Evangelia K Papachristou; Rebecca Broome; Simon J Johnston; Stacey E P Joosten; Andrew R Green; Sanjeev Kumar; Julia Jones; Soleilmane Omarjee; Ruben Alvarez-Fernandez; Silvia Glont; Sarah J Aitken; Kamal Kishore; Danya Cheeseman; Emad A Rakha; Clive D'Santos; Wilbert Zwart; Alasdair Russell; Cathrin Brisken; Jason S Carroll

doi:10.1016/j.ccell.2020.06.007

IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis

Rasmus Siersbæk, Valentina Scabia, Sankari Nagarajan, Igor Chernukhin, Evangelia K Papachristou, Rebecca Broome, Simon J Johnston, Stacey E P Joosten, Andrew R Green, Sanjeev Kumar, Julia Jones, Soleilmane Omarjee, Ruben Alvarez-Fernandez, Silvia Glont, Sarah J Aitken, Kamal Kishore, Danya Cheeseman, Emad A Rakha, Clive D'Santos, Wilbert ZwartAlasdair Russell, Cathrin Brisken, Jason S Carroll

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

42 Downloads (Pure)

Abstract

The cytokine interleukin-6 (IL6) and its downstream effector STAT3 constitute a key oncogenic pathway, which has been thought to be functionally connected to estrogen receptor α (ER) in breast cancer. We demonstrate that IL6/STAT3 signaling drives metastasis in ER+ breast cancer independent of ER. STAT3 hijacks a subset of ER enhancers to drive a distinct transcriptional program. Although these enhancers are shared by both STAT3 and ER, IL6/STAT3 activity is refractory to standard ER-targeted therapies. Instead, inhibition of STAT3 activity using the JAK inhibitor ruxolitinib decreases breast cancer invasion in vivo. Therefore, IL6/STAT3 and ER oncogenic pathways are functionally decoupled, highlighting the potential of IL6/STAT3-targeted therapies in ER+ breast cancer.

Originalsprog	Engelsk
Tidsskrift	Cancer Cell
Vol/bind	38
Udgave nummer	3
Sider (fra-til)	412-423.e9
ISSN	1535-6108
DOI	https://doi.org/10.1016/j.ccell.2020.06.007
Status	Udgivet - 14. sep. 2020
Udgivet eksternt	Ja

Bibliografisk note

Dokumenter og links

10.1016/j.ccell.2020.06.007

Open Access VersionAccepteret manuskript, 3,94 MBLicens: CC BY-NC-ND

SDU link

Tjek adgangen til materialet i Syddansk Universitetsbiblioteks søgemaskine

Citationsformater

Siersbæk, R., Scabia, V., Nagarajan, S., Chernukhin, I., Papachristou, E. K., Broome, R., Johnston, S. J., Joosten, S. E. P., Green, A. R., Kumar, S., Jones, J., Omarjee, S., Alvarez-Fernandez, R., Glont, S., Aitken, S. J., Kishore, K., Cheeseman, D., Rakha, E. A., D'Santos, C., ... Carroll, J. S. (2020). IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis. Cancer Cell, 38(3), 412-423.e9. https://doi.org/10.1016/j.ccell.2020.06.007

@article{6bd13f9680e64c95902f22fe1718ebd8,

title = "IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis",

abstract = "The cytokine interleukin-6 (IL6) and its downstream effector STAT3 constitute a key oncogenic pathway, which has been thought to be functionally connected to estrogen receptor α (ER) in breast cancer. We demonstrate that IL6/STAT3 signaling drives metastasis in ER+ breast cancer independent of ER. STAT3 hijacks a subset of ER enhancers to drive a distinct transcriptional program. Although these enhancers are shared by both STAT3 and ER, IL6/STAT3 activity is refractory to standard ER-targeted therapies. Instead, inhibition of STAT3 activity using the JAK inhibitor ruxolitinib decreases breast cancer invasion in vivo. Therefore, IL6/STAT3 and ER oncogenic pathways are functionally decoupled, highlighting the potential of IL6/STAT3-targeted therapies in ER+ breast cancer.",

keywords = "FOXA1, IL6, STAT3, breast cancer, estrogen receptor, metastasis, mouse intraductal xenograft model, pioneer factor",

author = "Rasmus Siersb{\ae}k and Valentina Scabia and Sankari Nagarajan and Igor Chernukhin and Papachristou, {Evangelia K} and Rebecca Broome and Johnston, {Simon J} and Joosten, {Stacey E P} and Green, {Andrew R} and Sanjeev Kumar and Julia Jones and Soleilmane Omarjee and Ruben Alvarez-Fernandez and Silvia Glont and Aitken, {Sarah J} and Kamal Kishore and Danya Cheeseman and Rakha, {Emad A} and Clive D'Santos and Wilbert Zwart and Alasdair Russell and Cathrin Brisken and Carroll, {Jason S}",

year = "2020",

month = sep,

day = "14",

doi = "10.1016/j.ccell.2020.06.007",

language = "English",

volume = "38",

pages = "412--423.e9",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "3",

}

Siersbæk, R, Scabia, V, Nagarajan, S, Chernukhin, I, Papachristou, EK, Broome, R, Johnston, SJ, Joosten, SEP, Green, AR, Kumar, S, Jones, J, Omarjee, S, Alvarez-Fernandez, R, Glont, S, Aitken, SJ, Kishore, K, Cheeseman, D, Rakha, EA, D'Santos, C, Zwart, W, Russell, A, Brisken, C & Carroll, JS 2020, 'IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis', Cancer Cell, bind 38, nr. 3, s. 412-423.e9. https://doi.org/10.1016/j.ccell.2020.06.007

TY - JOUR

T1 - IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis

AU - Siersbæk, Rasmus

AU - Scabia, Valentina

AU - Nagarajan, Sankari

AU - Chernukhin, Igor

AU - Papachristou, Evangelia K

AU - Broome, Rebecca

AU - Johnston, Simon J

AU - Joosten, Stacey E P

AU - Green, Andrew R

AU - Kumar, Sanjeev

AU - Jones, Julia

AU - Omarjee, Soleilmane

AU - Alvarez-Fernandez, Ruben

AU - Glont, Silvia

AU - Aitken, Sarah J

AU - Kishore, Kamal

AU - Cheeseman, Danya

AU - Rakha, Emad A

AU - D'Santos, Clive

AU - Zwart, Wilbert

AU - Russell, Alasdair

AU - Brisken, Cathrin

AU - Carroll, Jason S

PY - 2020/9/14

Y1 - 2020/9/14

N2 - The cytokine interleukin-6 (IL6) and its downstream effector STAT3 constitute a key oncogenic pathway, which has been thought to be functionally connected to estrogen receptor α (ER) in breast cancer. We demonstrate that IL6/STAT3 signaling drives metastasis in ER+ breast cancer independent of ER. STAT3 hijacks a subset of ER enhancers to drive a distinct transcriptional program. Although these enhancers are shared by both STAT3 and ER, IL6/STAT3 activity is refractory to standard ER-targeted therapies. Instead, inhibition of STAT3 activity using the JAK inhibitor ruxolitinib decreases breast cancer invasion in vivo. Therefore, IL6/STAT3 and ER oncogenic pathways are functionally decoupled, highlighting the potential of IL6/STAT3-targeted therapies in ER+ breast cancer.

AB - The cytokine interleukin-6 (IL6) and its downstream effector STAT3 constitute a key oncogenic pathway, which has been thought to be functionally connected to estrogen receptor α (ER) in breast cancer. We demonstrate that IL6/STAT3 signaling drives metastasis in ER+ breast cancer independent of ER. STAT3 hijacks a subset of ER enhancers to drive a distinct transcriptional program. Although these enhancers are shared by both STAT3 and ER, IL6/STAT3 activity is refractory to standard ER-targeted therapies. Instead, inhibition of STAT3 activity using the JAK inhibitor ruxolitinib decreases breast cancer invasion in vivo. Therefore, IL6/STAT3 and ER oncogenic pathways are functionally decoupled, highlighting the potential of IL6/STAT3-targeted therapies in ER+ breast cancer.

KW - FOXA1

KW - IL6

KW - STAT3

KW - breast cancer

KW - estrogen receptor

KW - metastasis

KW - mouse intraductal xenograft model

KW - pioneer factor

U2 - 10.1016/j.ccell.2020.06.007

DO - 10.1016/j.ccell.2020.06.007

M3 - Journal article

C2 - 32679107

SN - 1535-6108

VL - 38

SP - 412-423.e9

JO - Cancer Cell

JF - Cancer Cell

IS - 3

ER -

IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis

Abstract

Bibliografisk note

Dokumenter og links

SDU link

Fingeraftryk

Citationsformater